Asdera

We plan a phase 3 trial to get FDA-approval for a drug (pat. pending) to prevent children developing autism from becoming non-verbal (life-long disability).

  • Stage $500K in TTM Revenue
  • Industry Biotechnology
  • Location New York, NY, US
  • Currency USD
  • Founded September 2013
  • Employees 1
  • Incorporation Type LLC
  • Website asdera.com

Company Summary

Asdera is a virtual company aiming to obtain an NDA for a drug to prevent disruption of active language development in children with early signs of autism and prodromal signs of mutism. A CRO will oversee the manufacturing of the drug and, after obtaining an IND, assume management responsibility for the conduct the clinical trial. Upon approval of the drug, the rights to the drug will be sold to a pharmaceutical company.

Team

  • Knut Wittkowski
    Founder, ASDERA; Senior Research Associate, The Rockefeller University; Director, Biostatistics, Epidemiology & Research Design, Center for Clinical and Translational Science; apl. Professor, Eberhard-Karls-University, Tübingen

    Dr. Wittkowski has 30 years of experience in clinical trial design and developed the statistical approach (US Pat 7664616) that implicated the drug target.
    His education: statistics (MS), computer science (PhD), and medical biometry (ScD).

  • John Jay Gargus, MD, PhD
    Professor of Pediatrics, Physiology & Biophysics; Director, Center for Autism Research and Translation; PI, Drug Discovery Platform for Autism, University of California Irvine

    A major research thrusts on-going in the Gargus lab is a functional genomics approach to ion pumps and channels as candidate genes in common complex polygenic disease, a field he recently covered in invited reviews. The lab defined ATP1A2 as a migraine gene. In 2009, Dr. Gargus published the review "Genetic calcium signaling abnormalities in the CNS: seizures, migraine and autism". Previously, he has done extensive research on fenamates.

  • Gabrielle Gold-von Simson, MD, MSc
    Assistant Professor of Pediatrics; Medical Director, Inpatient Pediatrics; Director Clinical Research Center, NYU School of Medicine; PI, Drug Development Educational Programm (NIDDK); New York University Langone Medical Center

    Dr. Gold-von Simson's is a board-certified pediatrician with a Master's degree in Clinical Investigation. Her current research involves pediatric clinical trials, and she has also been involved with the formulation of compounds for dose escalation, safety, and efficacy trials. She is the Course Director for the GSAS's Drug Development course and is actively involved in teaching programs for drug development and entrepreneurship.

Advisors

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free